|
|
[×ÊÔ´]
ҽѧ¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ
¸ù¾ÝҽѧÔÓÖ¾±à¼¹ú¼ÊίԱ»áÖÆ¶¨µÄ¡¶ÉúÎïҽѧÔÓ־Ͷ¸åͳһҪÇó¡·Ò»ÆªÉúÎïҽѧ¿ÆÑÐÂÛÎÄ£¨ÒÔϼò³Æ¡°ÂÛÎÄ¡±£©Ó¦°üÀ¨ÒÔÏÂ12¸ö²¿·Ö£º
1.±êÌâ(title)
2.ÕªÒª(abstract)
3.ÒýÑÔ(introduction)
4.²ÄÁÏÓë·½·¨(materials and methods)
5.½á¹û(results)
6.ÌÖÂÛ(discussion)
7.ÖÂл(acknowledgements)
8.²Î¿¼ÎÄÏ×(references)
9.²åͼ˵Ã÷(legends)
10.²åͼ(figures)
11.±í¸ñ(tables)
12.ÕÕÆ¬ºÍ˵Ã÷(plates and explanations)
ÒÔÉϳý7¡¢9¡¢10¡¢11¡¢12²¿·ÖÒòʵ¼ÊÇé¿ö²»ÐèÒªÍ⣬ÆäËû¸÷²¿·ÖÊÇһƪÂÛÎıز»¿ÉÉÙµÄÄÚÈÝ¡£
1¡¢ÒýÑÔ²¿·Ö
×ܵÄÒªÇó£º
˵Ã÷Ñо¿µÄ×ÜÌ巶ΧºÍÄ¿µÄ¡£
¾ßÌåÒªÇó£º
a. ±³¾°¨c˵Ã÷ËùÑо¿ÎÊÌâµÄĿǰ×ÜÌåÇé¿ö»òÀúÊ·(statement of general area or history ofproblem)£»
b. ÒâÒå¨c˵Ã÷Ñо¿µÄÒâÒå»ò±ØÒªÐÔ(statement of importance or need)£»
c.½øÕ¹¨c˵Ã÷ÓйظÃÎÊÌâµÄÏÈÓз¢ÏÖ¡¢±¨¸æ»òÑо¿(statement of previous findings,reports orstudies)¡£³ÂÊöÕⲿ·ÖÄÚÈÝʱһ°ãÒªÓÐÒýÎÄ(citations)£»
d. Ä¿µÄ¨c˵Ã÷±¾Ñо¿µÄÄ¿µÄ(statement of purpose of current study)£»
e. ·¶Î§¨c˵Ã÷ÒªÑо¿ÎÊÌâµÄ¾ßÌ巶Χ(statement of specific area of problem to bestudied)
2¡¢²ÄÁÏÓë·½·¨²¿·Ö
×ܵÄÒªÇó£º
½á¹ûµÄ¿ÉÖØÑÝÐÔ¡¢·½·¨µÄ¿É*ÐÔÒÔ¼°Ç°ºóµÄÂß¼ÐÔ¡£
¾ßÌåÒªÇó£º
a. ¼òҪ˵Ã÷Ñо¿Éè¼Æ(study design/protocol)£¬È磺»Ø¹Ë(retrospective/review)£¬Ç°Õ°(prospective)£¬ÁÙ´²(clinical)£¬¶¯Îï(animal)£¬ÊµÑé(experimental)£¬»îÌåÄÚ(in vivo) »îÌåÍâ(in vitro)£¬Ôλ(in situ) Ëæ·Ã(follow-up)£¬¶ÔÕÕ(controlled)£¬Ëæ»ú(random/randomized)£¬Ë«Ã¤½»*(double- blind crossover)£¬ÈËȺ(population/cohort/migrant)£¬¶Ô±È(comparative)£¬Á÷Ðв¡Ñ§(epidemiological) µÈÑо¿ÐÔÖÊ£»
b. Ïêϸ˵Ã÷Ñо¿¶ÔÏó(subject) Çé¿ö£¬°üÀ¨Ñо¿ÈËÔ±(student)£¬±»Ñо¿µÄÈË(client) ºÍ¶¯Îï(animal) µÄÐÔ±ð(***)¡¢ÄêÁä(age)£¬ÎïÖÖ(species)£¬Æ·ÖÖ(breed) ÉúÀí״̬(physiological state)£»Î¢ÉúÎïÔòҪ˵Ã÷Æä¾úÖê(strain)£¬ÑªÇåÐÍ(serotype) ¼°ÆäËûÇø±ðÌØÐÔ(identity characteristics)£»
c. Ëæ»ú·Ö×é·Ö×é·½·¨(methods of any random assignment of subjects togroups) ºÍÑ¡Ôñ±ê×¼(criteria for admission to study groups)£»
d. Ïêϸ˵Ã÷ËùÓõÄÒ©Îï(drug)£¬¼¤ËØ(hormone)£¬ÊÔ¼Á(reagent) ºÍÆäËû»¯Ñ§Æ·(chemical) µÄÃû³Æ¡¢É̱ê(trademark)¡¢Éú²ú³§¼Ò(manufacturer)¼°ËùÔÚµØ(location)
e. ¼òҪ˵Ã÷²â¶¨·½·¨(method of measurement)£¬°üÀ¨Ãû³Æ£¬ÒýÎÄºÍÆ«²î(variations);
f. ¼òҪ˵Ã÷ͳ¼ÆÑ§·ÖÎö·½·¨(method of statistic analysis)
Õⲿ·ÖµÄ³ÂÊö³ÌÐòÒ»°ãΪ£ºÑо¿Éè¼Æ¡úÑо¿¶ÔÏóÐÔÖÊ¡ú´¦Àí/¸ÉÔ¤·½·¨¡ú²â¶¨/¹Û²ìÊֶΡúͳ¼Æ·ÖÎö¡£
³ýָʾÐÔ˵Ã÷Í⣬È磺¡°²¡ÈË×ÊÁϼû±í1¡±(data of the patients are shown in table 1) ¡°²ÄÁÏÓë·½·¨¡±ºÍ¡°½á¹û¡±Á½²¿·ÖÒ»ÂÉÓùýȥʱ±í´ï¡£
3¡¢½á¹û²¿·Ö
×ܵÄÒªÇó£º
ÈÃÑо¿µÄ¿Í¹Û½á¹û˵»°£¬²»ÒªÌíÖ¦¼ÓÒ¶¡£
¾ßÌåÒªÇó£º
a. ¶ÔËù»ñ½á¹û½øÐиÅÊö(overview of the results);
b. ˵Ã÷Ëù»ñ×ÊÁÏ»òÊý¾ÝµÄͳ¼ÆÒâÒå(statistical significance);
ͳ¼ÆÖ§³Ö(statisticalsupport)£¬°üÀ¨Í¼£¬±í£¬ÕÕÆ¬µÈ(·²ÓÃͼ±í±íʾµÄÄÚÈݲ»ÔÙÓÃÎÄ×ÖÏêÊö)¡£²»ÒªÓÃÄ£ÀâÁ½¿ÉµÄ´Ê»ò¶ÌÓï±íÊö½á¹û£¬È磺¡°theresults tended to be greater than¡¡±¡£
4¡¢ÌÖÂÛ²¿·Ö
×ܵÄÒªÇó£º
ÓëÏÈÓÐÑо¿Ïà±È£¬±¾Ñо¿ÓкÎÒâÒå¡£
¾ßÌåÒªÇó£º
a. ¼òҪ˵Ã÷Ñо¿±³¾°(background)
b. ¼òÒª½éÉÜ×ܵķ¢ÏÖ(general findings);
c. ½éÉܾßÌåÒªµã(introduction of points)
d. ÓëÏÖÓз¢ÏÖ(ÈôÓÐ)½øÐбȽÏ(comparison in the context of other studies)
e. ÒâÒå(suggested meaning)
f. ½áÂÛ(conclusion)
g. ǰհÑо¿(future studies)
½áÂÛÍùÍùÊÇÂÛÎÄÖÐ×ҲÊÇ×îÄÑдµÄ²¿·Ö£¬Ö÷ÒªÔÒòÊÇ×÷ÕßÒª¶ÔÑо¿½á¹ûºÍ·¢ÏÖ½øÐзÖÎö¡¢Íƶϡ¢ÑÝÒïºÍÍÆÀí£¬ÒªÇó×÷Õß¾ßÓкÜÇ¿Â߼˼άÄÜÁ¦ºÍÓ¢ÓïÎÄ×Ö×éÖ¯ÄÜÁ¦¡£´ËÍ⣬Õⲿ·Öʱ̬±È½Ï¸´ÔÓ£¬Òª·ÖÇåʵÑé¹ý³ÌºÍ½á¹û(¹ýȥʱ)Óë·ÖÎöÒâ¼û(È·¶¨£ºÏÖÔÚʱ;²»È·¶¨»ò¼ÙÉ裺¹ýȥʱ)µÄÇø±ð;ËûÈËÑо¿½á¹û(¹ýȥʱ»òÏÖÔÚÍê³Éʱ)Óë±¾Ñо¿½á¹û(¹ýȥʱ)µÄÇø±ð;ÆÕ±éÊÊÓõĽáÂÛ(ÏÖÔÚʱ)ÓëÖ»ÊÊÓñ¾Ñо¿µÄ½áÂÛ(¹ýȥʱ)µÄÆä±ðµÈ¡£Òò´Ë£¬¶ÔÓÚhowever, may, might, could, would, possibly,probably, be likely to µÈ´Ê(×é)µÄʹÓÃÒÔ¼°we believe (think/consider) that, to ourknowledge, in our experience (practice) µÈ²åÈëÓïµÄʹÓþÍÏԵøñÍâÖØÒª¡£
5¡¢ÖÂл²¿·Ö
×ܵÄÒªÇó£º
ÖÂл´ÊºÍÖÂл·½Ê½±ØÐëÕ÷µÃÊÜлÈË»òµ¥Î»µÄͬÒâ¡£
6¡¢²Î¿¼ÎÄÏ×
×ܵÄÒªÇó£º
referencestyles should be specific to eachjournal,¼È£º¸ù¾Ý¸÷ÔÓÖ¾µÄ¾ßÌåÒªÇó£¬ÒòΪ¸÷ÔÓÖ¾¶Ô²Î¿¼ÎÄÏײ¿·ÖµÄ±àÅÅ˳ÐòºÍ¸ñʽ²»¾¡Í³Ò»¡£
ÏÖ½«urmsbjÒªÇóµÄ20¶àÖֲο¼ÎÄÏ×ÖÐ×î³£¼ûµÄ5ÖÖ¸ñʽÁоÙÈçÏ£º
1) vega kj,pina i,krevsky b.heart transplantation is associated with anincreased risk for pancreatobiliary disease.ann intern med 1996 jun1;124(11):980-3. [±ê×¼ÔÓÖ¾ÎÄÕÂ]
2) the cardiac society of australia and new zealand.clinical excisestress testing:safety and performance guidelines.med j aust1996;164:282-4. [×÷ÕßÊǸö×éÖ¯]
3) cancer in south africa[editorial].s afr med j 1984;84:15. [ÎÞ×÷ÕßÃû]
4) shen hm,zhang qf.risk assessment of nickel cardiogenicity andoccupational lung cancer.environ health perspect 1994;102 suppl1:275-82.[ijÔÓÖ¾Ôö¿¯]
5) browell da,lennard tw.immunologic status of the cancer patient andthe effects of blood transfusion on antitumor responses.curr opin gensurg 1993;325-33 [ÎÞÆÚÎÞ¾í]
7¡¢²åͼ˵Ã÷
×ܵÄÒªÇó£º
²åͼ˵Ã÷ÒªÁíҳ˫ÐдòÓ¡¡£µ±²åͼÖÐÓмýÍ·(arrow)¡¢·ûºÅ(symbol)¡¢Êý×Ö(number)»ò×Öĸ(letter)ʱ£¬ÒªÔÚÕⲿ·Ö(²»ÊÇÔÚ²åͼҳÉÏ)¶ÔÆä·½Ïò¡¢Î»ÖõÈ×÷³ö·Ç³£Ã÷È·µÄ˵Ã÷¡£
8¡¢²åͼ
×ܵÄÒªÇó£º
designyour figures for the appropriatereduction,¼´£º²åͼҪ°´ÔÓÖ¾µÄ°æÃæ´óС±ÈÀý½øÐÐѹËõ;²»Òª°Ñ²åͼÅijÉÕÕÆ¬¡£
9¡¢±í¸ñ
×ܵÄÒªÇó£º
atable should be a totally self-contained unit ofinformation,¼´£º±í¸ñÒª×÷Ϊһ¸ö¶ÀÁ¢µÄÐÅÏ¢µ¥Î»ÁíÒ³´òÓ¡¡£±í¸ñÒª¼òÃ÷Çå³þ£¬ÍêÕû(±êÌâ¡¢ÄÚÈݺͽÅ×¢)£¬¼´Ê¹Ö»ÓÐÒ»Õűí¸ñÒ²Òª±êtable1¡£
ÔÚÂÛÎÄд×÷ÉÏ»¹ÓÐʲô²»¶®µÃ¿ÉÒÔ¿´¸½¼þÊÓÆµ£¬Ò»¹²ÓÐ26¸öÊÓÆµ¿ÉÒÔѧϰ£¬¿ÉÒÔÈÃÄã¸üÖ±¹ÛµÄѧϰ~![ҽѧ¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ]()
![ҽѧ¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ-1]()
|
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com
- ¸½¼þ 1 : 26¸öSCIд×÷½Ì³Ì.docx
2019-05-22 11:16:00, 68.88 K
» ²ÂÄãϲ»¶
|